Peer-reviewed veterinary case report
Safety of combined CCNU and toceranib cancer treatment in dogs
By Pan, X et al.·Published in Veterinary and comparative oncology·2016·School of Veterinary Medicine and the Carbone Cancer Center, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Safety evaluation of combination CCNU and continuous toceranib phosphate (Palladia(®) ) in tumour-bearing dogs: a phase I dose-finding study.
- Species:
- dog
Plain-English summary
A group of dogs with various types of tumors, including lymphoma and sarcoma, were treated with a combination of two cancer medications: CCNU and toceranib (Palladia). The treatment was generally well tolerated, with some dogs showing positive responses, including one complete response and several partial responses. The maximum safe dose for CCNU when used with toceranib was found to be 50 mg/m² every three weeks. This study suggests that this combination could be a promising option for dogs with certain cancers, but further research is needed to confirm its effectiveness.
People also search for: dog cancer treatment options · lymphoma in dogs prognosis · CCNU side effects in dogs
Abstract
While maintaining a standard toceranib dosage [2.75 mg kg(-1) , PO, every other day (EOD)], three dose-escalating CCNU cohorts up to and including 60 mg m(-2) , PO, q3wk, were completed. The dose-limiting toxicities (DLT) for the combination were neutropenia and the maximum tolerated dose (MTD) for CCNU when given with continuous toceranib was determined to be 50 mg m(-2) , q3wk. While activity is not a primary objective of phase I trials, we observed one complete (lymphoma) and four partial responses (lymphoma, sarcoma, undifferentiated carcinoma and prostatic carcinoma) and two dogs experienced stable disease for >6 weeks [gastric adenocarcinoma and metastatic multilobulated osteochondrosarcoma (MLO)] for an objective response rate of 38.4% and a biological response rate of 53.8%. Concurrent continuous toceranib (2.75 mg kg(-1) , EOD) and pulse dose CCNU (50 mg m(-2) , q3wk) was well tolerated. Phase II effectiveness and phase III prospective randomized trials should further interrogate the potential activity of this combination.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/24735385/